Cover Image
市場調查報告書

類鼻疽感染疾病 : 開發中產品分析

Burkholderia Infections - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 293881
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
類鼻疽感染疾病 : 開發中產品分析 Burkholderia Infections - Pipeline Review, H1 2016
出版日期: 2016年06月22日 內容資訊: 英文 76 Pages
簡介

類鼻疽感染疾病是由類鼻疽溶鈣磷細菌所引起的感染疾病,症狀的發展有從低燒開始的肺炎、咳嗽、充血、呼吸急促、喘鳴。發病要素為免疫系統衰弱和肺部疾病,治療則使用抗生劑。

本報告提供類鼻疽感染疾病治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

類鼻疽感染疾病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • Arno Therapeutics, Inc.
  • Bavarian Nordic A/S
  • Emergent BioSolutions Inc.
  • Eumedica SA
  • Grifols, S.A.
  • NanoBio Corporation
  • Sarepta Therapeutics, Inc.
  • Soligenix, Inc.
  • Syntiron LLC
  • TGV-Laboratories
  • Vault Pharma Inc.

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 關註資訊和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8190IDB

Summary

Global Markets Direct's, 'Burkholderia Infections - Pipeline Review, H1 2016', provides an overview of the Burkholderia Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burkholderia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkholderia Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Burkholderia Infections
  • The report reviews pipeline therapeutics for Burkholderia Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Burkholderia Infections therapeutics and enlists all their major and minor projects
  • The report assesses Burkholderia Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Burkholderia Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Burkholderia Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Burkholderia Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Burkholderia Infections Overview
  • Therapeutics Development
    • Pipeline Products for Burkholderia Infections - Overview
    • Pipeline Products for Burkholderia Infections - Comparative Analysis
  • Burkholderia Infections - Therapeutics under Development by Companies
  • Burkholderia Infections - Therapeutics under Investigation by Universities/Institutes
  • Burkholderia Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Burkholderia Infections - Products under Development by Companies
  • Burkholderia Infections - Products under Investigation by Universities/Institutes
  • Burkholderia Infections - Companies Involved in Therapeutics Development
    • Arno Therapeutics, Inc.
    • Bavarian Nordic A/S
    • Emergent BioSolutions Inc.
    • Eumedica SA
    • Grifols, S.A.
    • NanoBio Corporation
    • Sarepta Therapeutics, Inc.
    • Soligenix, Inc.
    • Syntiron LLC
    • TGV-Laboratories
    • Vault Pharma Inc.
  • Burkholderia Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Inhibit Nucleoporin p62 for Burkholderia Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-13 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARD-3100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARD-3150 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Burkholderia pseudomallei vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Burkholderia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Burkholderia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dusquetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EV-035 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-072 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melioidosis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Mul-1867 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NB-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SGX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SGX-943 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • temocillin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPI-231 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Burkholderia Infections - Dormant Projects
  • Burkholderia Infections - Discontinued Products
  • Burkholderia Infections - Product Development Milestones
    • Featured News & Press Releases
      • May 31, 2016: FDA Grants Soligenix "Fast Track" Designation for SGX943 for the Treatment of Melioidosis
      • Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
      • Aug 14, 2014: US DTRA to fund preclinical work on Evolva's antibiotic GC-072
      • Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development
      • Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development
      • Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
      • Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC
      • Oct 15, 2009: NanoBio's Nanoemulsion Kills Drug-Resistant Bacteria Found In Cystic Fibrosis Patients
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Burkholderia Infections, H1 2016
  • Number of Products under Development for Burkholderia Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Burkholderia Infections - Pipeline by Arno Therapeutics, Inc., H1 2016
  • Burkholderia Infections - Pipeline by Bavarian Nordic A/S, H1 2016
  • Burkholderia Infections - Pipeline by Emergent BioSolutions Inc., H1 2016
  • Burkholderia Infections - Pipeline by Eumedica SA, H1 2016
  • Burkholderia Infections - Pipeline by Grifols, S.A., H1 2016
  • Burkholderia Infections - Pipeline by NanoBio Corporation, H1 2016
  • Burkholderia Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2016
  • Burkholderia Infections - Pipeline by Soligenix, Inc., H1 2016
  • Burkholderia Infections - Pipeline by Syntiron LLC, H1 2016
  • Burkholderia Infections - Pipeline by TGV-Laboratories, H1 2016
  • Burkholderia Infections - Pipeline by Vault Pharma Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Burkholderia Infections - Dormant Projects, H1 2016
  • Burkholderia Infections - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Burkholderia Infections, H1 2016
  • Number of Products under Development for Burkholderia Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top